Nexel Overview
- Year Founded
-
2012
- Status
-
Private
- Employees
-
31
- Latest Deal Type
-
Later Stage VC
- (In Progress)
- Investors
-
19
Nexel General Information
Description
Operator of a biotechnology company intended to provide drug discovery pipelines to treat diseases. The company develops high-quality iPSC-derived cell products through embryonic stem cell technology, enabling clients to conquer unmet medical needs and iPSC technology.
Contact Information
Website
www.nexel.co.krCorporate Office
- 8th Floor, 55 Magokdong-ro
- Gangseo-gu
- Seoul, 07802
- South Korea
Corporate Office
- 8th Floor, 55 Magokdong-ro
- Gangseo-gu
- Seoul, 07802
- South Korea
Nexel Timeline
Nexel Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 9. Later Stage VC | 12-Jun-2026 | In Progress | Generating Revenue | |||
| 8. Later Stage VC | 05-Jun-2026 | Completed | Generating Revenue | |||
| 7. Later Stage VC | 01-Sep-2023 | Completed | Generating Revenue | |||
| 6. Secondary Transaction - Private | 01-Aug-2021 | Completed | Generating Revenue | |||
| 5. Later Stage VC (Series B) | 16-Apr-2021 | Completed | Generating Revenue | |||
| 4. Later Stage VC (Series B) | 01-Aug-2019 | Completed | Generating Revenue | |||
| 3. Later Stage VC (Series A) | 01-Dec-2017 | Completed | Generating Revenue | |||
| 2. Accelerator/Incubator | 01-Mar-2017 | Completed | Generating Revenue | |||
| 1. University Spin-Out | 24-Sep-2012 | Completed | Generating Revenue |
VC Exit Predictor
See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.
Opportunity Score
Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.
Exit Type
Evaluates the likelihood of a successful exit for investors, and the most likely exit type.
Nexel Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
Nexel Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Nexel Investors (19)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Susung Asset Management | Asset Manager | Minority | ||
| Synergy Partners | Investment Bank | Minority | ||
| Tiger Asset Management | Hedge Fund | Minority | ||
| BSK Investment | Venture Capital | Minority | ||
| Comes Investment | Venture Capital | Minority |
Nexel Investments (2)
Nexel’s most recent deal was a Joint Venture with TriNebula Cell Tech. The deal was made on 09-Oct-2026.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| TriNebula Cell Tech | 09-Oct-2026 | Joint Venture | Media and Information Services (B2B) | ||
| Celogics | 26-Oct-2021 | Joint Venture | Biotechnology |
Nexel FAQs
-
When was Nexel founded?
Nexel was founded in 2012.
-
Where is Nexel headquartered?
Nexel is headquartered in Seoul, South Korea.
-
What is the size of Nexel?
Nexel has 31 total employees.
-
What industry is Nexel in?
Nexel’s primary industry is Drug Discovery.
-
Is Nexel a private or public company?
Nexel is a Private company.
-
What is Nexel’s current revenue?
The current revenue for Nexel is .
-
How much funding has Nexel raised over time?
Nexel has raised $31.6M.
-
Who are Nexel’s investors?
Susung Asset Management, Synergy Partners, Tiger Asset Management, BSK Investment, and Comes Investment are 5 of 19 investors who have invested in Nexel.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process
